R(-)-deprenyl (L-deprenyl or selegiline) is a typical selective inhibitor of monoamine oxidase (MAO) type B, an enzyme that preferentially deaminates phenylethylamine and benzylamine. The functionally different forms of MAO, denoted "A" and "B," were first reported by Johnston (1968) . The molecular differences between these two enzymes derive from differences in their primary amino acid sequences (Bach et al., 1988) in that they are encoded by separate gene loci (see Shih, 199 1) . Deprenyl binds to MAO-B and irreversibly inhibits the enzyme, similarly to other suicidal inhibitors in the flavin adenine dinucleotide (FAD)-binding class of compounds (see (Youdim, 1978) . R(-)-deprenyl was reported by Birkmayer et al. (1975) to increase the efficacy of levodopa therapy in the treatment of Parkinson's disease (PD) by reducing dopamine (DA) catabolism by MAO-B (Birkmayer et al., 1983) . More recently, R(-)-deprenyl monotherapy has been reported to slow the progression of neurological deficits in PD (Parkinson Study Group, 1989 , 1993 Tetrud and Langston, 1989; Poungvarin and Viriyavejakul, 1990; Allain et al., 199 I; Myllyla et al., 1992) and cognitive decline in Alzheimer's disease (AD) (Sunderland et al., !987; Tariot et al., 1987; Campi et al., 1990; Falsaperla et al., 1990; Monteverde et al., 1990; Piccinin et al., 1990; Goad et al., 1991; Mangoni et al., 1991; Martignoni et al., 1991; Schneider et al., 199 1) .
The extent of the beneficial effects of R( -)-deprenyl treatment in the two neurodegenerative diseases is controversial and the mechanisms underlying those benefits are unknown. The apparent slowing of the two diseases has been variously ascribed to (1) symptomatic actions caused by a decrease in DA catabolism resulting from the inhibition of MAO-B (see Lieberman et al., 1992) or by a facilitation of DA transmission by 2-phenylethylamine (2-PEA) (Paterson et al., 1990a,b) , (2) protection of neurons against toxic oxidative damage through the reduction of free radical formation (see Olanow and Calne, 1992) or (3) the CNS stimulant effect caused by the major catabolic products of R( -)-deprenyl, (-)-amphetamine, and (-)-methamphetamine (Karoum et al., 1982; Engberg et al., 1991) .
A previously unrecognized action of R( -)-deprenyl also might contribute to the beneficial effects in PD and AD. R( -)-deprenyl can increase the survival of damaged neurons or rescue them rather than just protect neurons from sustaining oxidative damage as previously supposed (see Tatton, 1993 , for a recent review). Experiments in mice showed that R( -)-deprenyl increases the survival of dopaminergic nigrostriatal neurons (dNSns) damaged by the parkinsonian toxin MPTP (Tatton and Greenwood, 199 i) , independently of blocking the conversion of MPTP to MPP+. R(-)-deprenyl reduced the death of dNSns by 60-70% when treatment was delayed for 72 hr after the completion of MPTP exposure. The delay in R(-)-deprenyl treatment allowed time for the complete conversion of MPTP to MPP+ (Yang et al., 1988) and for extensive damage to dNSns by the toxin (Linder et al., 1987). or vehicle (saline) intraperitoneally, acutely, and then every other day thereafter for 2 I d. On the 2 1 st day after the axotomy (P35), the animals were killed and perfused with 4% paraformaldehyde.
After removal, the brainstem was cryoprotected in 20% sucrose and frozen in -70°C methylbutane.
Serial 10 pm sections were cut through the entire length of the facial nucleus and every third section was incubated overnight with a polyclonal antibody directed against ChAT ( 1: 1000) at 4°C. The sections were then incubated in biotinylated goat anti-rabbit IgG and then with avidin-horseradish peroxidase (HRP). The visualization of immunoreactive cells was performed in a 0.05% solution ofdiaminobenzidine in 0.0 1% H,O,. Controls were carried out by incubating sections in nonimmune serum instead of primary antiserum.
The ChAT immunoreaction was used to unambiguously recognize motoneuron somata in the facial nucleus. Consecutive sections immediately adjacent to those that were ChAT immunoreacted were stained for Nissl substance in order to determine whether the numbers of Nisslstainable somata were the same as the number of ChAT-immunopositive somata. A decrease in ChAT synthesis has been reported in motoneurons after axotomy (Hoover and Hancock, 1985) . Conceivably, then, a decrease in ChAT synthesis sufficient to eliminate detectable
ChAT immunoreactivity in a proportion of the surviving motoneurons could result in the counts of Nissl-stained somata exceeding the number of ChAT+ somata in the same nucleus. Hence, the counts of Nisslstained somata and ChAT+ somata on immediately adjacent sections taken through the length of the facial nuclei allow for the differentiation of a loss of ChAT immunoreactivity from motoneuronal death caused by the axotomy (see Seniuk et al., 1990; Tatton and Greenwood, 1991; Tatton et al., 199 1; Salo and Tatton, 1992) . The remaining third of the serial sections were freeze dried and frozen for other studies.
R( -)-deprenyl also increases the survival of motoneurons after axotomy produced by facial nerve transection at postnatal day 14 (PI 4) . The motoneuronal death after facial nerve transection is thought to reflect the dependency of the immature motoneurons on trophic support that is axonally transported from the facial muscles (Crews and Wigston, 1990) . Reductions in motoneuronal death can be produced when neurotrophic factors like ciliary neurotrophic factor (CNTF) (Sendtner et al., 1990) brain-derived neurotrophic factor (BDNF) (Sendtner et al., 1992; Yan et al., 1992) or basic fibroblast growth factor (bFGF) (Grothe and Unsicker, 1992) are provided to the cut axons of the motoneuron.
Whether the R( -)-deprenyl-mediated reduction in motoneuron death involves MAO-B or MAO-A inhibition is uncertain. Doses of 10 mg/kg/2d of R( -)-deprenyl were used to rescue the immature facial motoneurons after axotomy . Those doses would cause greater than 70% inhibition of MAO-B, and some MAO-A inhibition as well, in adult rodents (Demarest et al., 1980) . The ED,, for MAO-B inhibition is 0.5 mg/kg in the adult rodent (Yu et al., 1992) . In vitro studies using newborn mouse cortex have shown decreased MAO-B activity relative to MAO-A activity when compared to the relative activity of the enzymes in adult cortical tissue (Yu and Hertz, 1982) . A similar increase in sensitivity of MAO-B activity to deprenyl inhibition in the immature P14 brainstem would result in significant MAO-B inhibition by doses of R( -)-deprenyl that are insufficient to inhibit MAO-B in adult rodents. We compared the MAO-A and MAO-B inhibition produced by the (+)-and the (-)-enantiomers of deprenyl in the P14 rat brainstem with the ability of the two enantiomers to increase facial motoneuronal survival after axotomy at P 14. The dosage relationships and the differences in the stereospecificity of MAO-B inhibition versus that of the increased motoneuronal survival showed that the increased survival is not mediated by the binding of R( -)-deprenyl, at the FAD site, of MAO-B that causes inhibition of the enzyme.
Somata containing nucleoli on ChAT-immunoreacted sections were counted using interference-contrast optics, while somata in Nissl-stained sections were counted in the facial nuclei using the nuclear size criteria developed by Oppenheim to differentiate motoneurons from intemeurons and glial cells in the brachial and lumbar spinal gray matter of the rat (Oppenheim, 1986) . Somata were counted only if they contained a nucleolus.
MAO inhibition. PI4 rats were injected with S(+)-deprenyl, R(-)-deprenyl, or saline and a period of 4 hr was allowed to pass before their subsequent death. At this time their brains were rapidly dissected out, and the portion of the brainstem between the upper mesencephalon and the medullary spinal junction was separated from the overlying cerebellum and isolated, rapidly frozen on dry ice, and stored at -80°C until assayed for MAO activity as described by Yu (1986) . Briefly, enzyme preparations of the above tissue were incubated at 37°C for 30 min in the presence of radiolabeled serotonin (5HT; 0.0005 M) or 2-phenylethylamine (2-PEA; 0.00001 M) in a final volume of 200 ~1. The reaction was terminated by the addition of 200 J 2 M citric acid. The oxidized products were extracted into 1 ml of toluene:ethyl acetate (1: 1 v/v) and radioactivity was assessed in 600 ~1 of this extract by scintillation counting. Reagents. Anti-ChAT antibody was purchased from Chemicon and goat anti-rabbit IgG and avidin-HRP complex was purchased from Vector Laboratories (Dimension Laboratories). R(-)-deprenyl and S(+)-deprenyl used in experiments carried out in parallel and employed for all results reported below were purchased from RBI Inc. (Natick, MA).
The MAO substrates used for the radioenzymatic determination of MAO-A and MAO-B activities, respectively, were 14C-5-HT and '"C-2-PEA, both obtained from New England Nuclear.
Statistics. The counts of neuronal somata for the unlesioned, lesioned, saline-treated, and deprenyl-treated animals; the ChAT-immunoreacted and Nissl-stained sections; and the brainstem MAO-A and MAO-B activity measures for the saline-treated and deprenyl-treated animals were pairwise evaluated using the Mann-Whitney U test (Siegel, 1956) . Significance was taken when the probability that the groups were drawn from the same population was less than 0.05. (The probability ofa given experimental group being drawn from the corresponding saline control C and D present medium-power photomicrographs of a ChAT-immunoreacted motoneuron, while E presents Nissl-stained motoneuron. The arrows mark the typical nucleoli used to count the somata. Scale bars: 82, 100 pm for Al, A2, BI, and B2; D, 50 pm for C-E. sections of rat facial nuclei ipsilateral to a facial nerve transection. In Figure 1 , the sections in AI and A2 were from salinetreated animals, while the sections in BI and B2 were from animals treated with the 0.0 1 mg/kg/2d of R( -)-deprenyl. The sections were taken at about the same rostrocaudal level of the facial nuclei in the two differently treated animals. Note the apparent similarity of the number and location of somata in the adjacent ChAT-immunoreacted and Nissl-stained sections (Fig.  lAI,A2 ,BI,B2).
The high-power photomicrographs in Figure 1 , C and D, are included to illustrate the nucleoli that were easily apparent on interference-contrast microscopy, and were used to count the facial motoneuron somata in ChAT-immunoreacted sections, while Figure 1 E shows Nissl-stained motoneurons meeting the nucleolar and nuclear size criteria for motoneurons (Oppenheim, 1986) . Somata that did not include a nucleolus were not counted to avoid double counting the somata of a single neuron. Using nuclear size and nucleolar criteria, the counts for Figure 1 , Al, A2, BI, and B2, were 11, 13, 22, and 23, respectively.
Figure 2 presents photomicrographs from the same sections but from facial nuclei contralateral to those shown in Figure 1 . In Figure 2 , A3 (ChAT immunoreacted) and A4 (Nissl stained) are for a saline-treated animal, while B3 (ChAT immunoreacted) and B4 (Nissl stained) are for a 0.01 mg/kg R(-)-deprenyltreated animal. Again, note the apparent correspondence of the motoneuron numbers in the immediately adjacent ChAT-immunoreacted and Nissl-stained sections. for one-third of the sections in each facial nucleus. Figure 4 depicts the mean +-SEM values for the counts of ChAT+ somata versus log,,, dose for the different treatment groups (n = 6-9 animals in each group). Figure 3 , Al and A2, presents overlaid longitudinal plots for animals that did not undergo facial nerve transection but were treated with saline (Fig. 3AI) or 10 mg/kg of R(-)-deprenyl ( Fig. 3A2 ) every second day from P14 to P35. They illustrate the reproducibility of the ChAT+ somal counts from animal to animal and that a high dose of R( -)-deprenyl (10 mg/kg/2d) did not alter the counts of ChAT+ somata in unlesioned animals. A probability value of 0.967 was found on statistical comparison of the counts, which showed that treatment with the 10 mg/kg dose of R(-)-deprenyl did not alter the numbers of ChAT+ somata in the unlesioned animals. Figure 3A2 presents overlaid longitudinal plots constructed for facial nuclei ipsilateral to a facial nerve section, while those in Figure 3A3 are for the contralateral nuclei in the same six saline-treated animals, The plots illustrate the reduction in the number of ChAT+ somata ipsilateral to the facial nerve section and show that the loss involved the whole length of the nuclei. The corresponding points in Figure 4 show that an average of 24.7% of the ChAT+ somata remained in the ipsilateral lesion, saline-treated group compared to the unlesioned, saline-treated group (p < 0.0001). The overlaid longitudinal plots in Figure  3A3 also illustrate the more variable loss of ChAT+ motoneuronal somata in the facial nucleus contralateral to the facial nerve section, which averaged 73.7% of the average value for the unlesioned, saline-treated group. This value represented a statistically significant reduction in the number of ChAT+ motoneurons in the facial nuclei contralateral to the facial nerve sections (p = 0.026) when compared to the saline, unlesioned group.
The overlaid plots in Figure 3 , B2 and B3, illustrate the in-creased number of ChAT+ motoneuron somata in all portions of the nuclei induced by treatment with 10 mg/kg of R(-)-deprenyl every 2 d. The corresponding points in Figure 4 show that the 10 mg/kg/2d R(-)-deprenyl treatment increased the average percentage of ChAT+ motoneuron somata in the ipsilateral facial nuclei from 24.7% to 48.5% (p = 0.002) and from 73.7% to 9 1.6% (p = 0.043). The remaining points in Figure 4 show that a dose of R(-)-deprenyl of 0.001 mg/kg/2d did not increase the percentage of ipsilateral (25.1%) or contralateral (78.5%) ChAT+ motoneuron somata, while the 0.005 and the 0.01 mg/kg/2d doses of H(-)-deprenyl both significantly increased the percentage of ChAT+ ipsilateral somata (51.5%). The 0.01 mg/kg/2d dose also significantly increased the percentage contralateral ChAT+ somata (9 1.7%), but the counts for the 0.005 mg/kg/2d dose did not reach significance (86.3%). The values in the parentheses next to the points in Figure 4 present the probability that values for each treatment group were drawn from the same population as the corresponding saline group.
Neither of the two doses of S(+)-deprenyl that were tested (0.1 and 10.0 mg/kg/2d, respectively) increased the percentages of the ipsilateral(26.2% and 28. I%, respectively) or the contralateral (80.3% and 77.8%, respectively) ChAT+ somata above the values for their corresponding saline groups. Figure 5 illustrates the relationships between the longitudinal rostrocaudal distributions constructed for the counts of the ChATt somata and the Nissl-stained somata in the alternate serial sections of the same nuclei for four selected treatment groups, while Table 1 Table 1 do not show a significant difference (p = 0.469) between the total Nissl and ChAT+ counts for the six nuclei. Figure 5 , BI and 82, presents similar longitudinal plots for facial nuclei ipsilateral to facial nerve sections that transected the peripheral axons of all of the motoneurons at P14. The similarity of the reduction in the numbers of both ChAT+ and Nissl-stained somata in all longitudinal portions of the nuclei showed that a majority of motoneurons had died by 2 1 d after axotomy. Table 1 shows slightly smaller mean values for the ChAT+ counts than the Nissl counts, but the values were not significantly different (p = 0.265). Figure 5 , Cl and C2, presents longitudinal distributions for ipsilateral facial nuclei in animals treated with 0.01 mg/kg/2d of R(-)-deprenyl.
The plots show an increase in the number of both ChAT+ and Nissl-stained somata in all portions of the nuclei, illustrating that the R(-)-deprenyl has approximately doubled the survival of the motoneurons. Table 1 shows that the increase is reflected similarly in the mean ChAT+ and Nissl somal counts. to each point show the probability that the values could be drawn for the same population as the saline controls. The ED,, for rescue by R(-)-deprenyl was 0.005 mg/kg/2d, while 10 mg/kg/2d of S(+)-deprenyl did not increase survival.
of surviving motoneurons from that shown for the saline-treated animals. Table 1 confirms that both the ChAT+ and the Nissl counts did not show an increase for the highest dose of S(+)-deprenyl when compared to the corresponding saline values. The values in Table 1 establish that the ChAT values at P35 reflected death of the facial motoneurons rather than a loss of ChAT immunoreactivity, and that doses of R(-)-deprenyl of 0.01 and 10.0 mg/kg/2d increased the survival of the motoneurons while a 0.00 1 mg/kg/2d dose of R( -)-deprenyl or 0.1 or 10.0 mg/kg/2d doses of S( +)-deprenyl did not increase the survival.
Sensitivity of deprenyl-mediated inhibition of PI4 rat brainstem MAO-B and MAO-B
The results obtained for MAO-B activity in the P14 brainstem are presented in Figure 6B , and those for MAO-A activity in Figure 6A . Figure 6A shows that MAO-A activity was not significantly reduced by either enantiomer until doses of lo-50 mg/kg were reached. The values in parentheses near each point present the t test probability that the deprenyl-treated values were drawn from the corresponding saline-treated group.
The plot in Figure 6B shows that both enantiomers inhibit 
MAO-B activity over different but overlapping dosage ranges.
The spacing of dosage values according to decades does not allow us to define exactly the levels of MAO-B activity for doses that were not tested, but it is sufficient to estimate an ED,, value for R(-)-deprenyl of about 0.1 mg/kg, which is lower than the value reported for adult rodents of 0.5 mg/kg. The ED,, value for S(+)-deprenyl in the P14 brainstem was approximately 2 mg/kg. Since the affinity, in vitro, of the (+)-enantiomer [S(+)-deprenyl] for MAO-B is reportedly lo-20-fold lower than that of the (-)-enantiomer in brain tissue from the adult rat (Robinson, 1985 ) the difference we have found in the intact P14 brainstem appears similar.
Discussion
Neuronal death is difficult to establish conclusively. Immunocytochemistry for marker proteins is essential to identify specific neuronal populations but suffers from the limitation that damaged nerve cells, like motoneurons, often decrease or halt the synthesis of some proteins (Hoover and Hancock, 1985) while increasing the synthesis of other proteins (Tetzlaff et al., 1988, 199 1) . Hence, a loss of immunoreactive somata may indicate neuronal death or a reactive decrease in protein synthesis. Motoneuronal somata can be premarked by the retrograde transport of an agent from their terminal areas (see Rootman et al., 198 1) and the number of remaining premarked somata used to estimate neuronal death (Crews and Wigston, 1990) . The technique carries the limitation that the entire population may not transport the marking substance, either due to incomplete delivery of the agent to the target tissues or due to inadequate uptake or retrograde transport by some of the neurons. If retrograde transport of a premarker is combined with immunocytochemistry for a marker protein (Tatton et al., 1991) it can be used to determine if a loss of immunoreactivity contributes to a reduction in the counts of immunoreactive somata but cannot offer absolute values for neuronal death unless the entire neuronal population is shown to have transported the premarker (Tatton et al., 1991) . Because the facial muscles are widely distributed over the rat face and adequate filling of all of the muscles with a premarker is difficult without extensive surgery, we chose to complement identification with a ChAT antibody with Nissl stain identification.
Counts of Nissl-stained somata can by themselves provide a good index of combined neuronal and glial loss in a nucleus or region but are complicated in terms of deducing neuronal death by possible atrophic changes in somal or nuclear size. Hence, atrophic neurons may no longer meet size criteria used to identify them. In the present study, we used the criteria of Oppenheim (1986) to identify motoneurons on serial sections through the length of each facial nucleus. In order to support the validity of the Nissl values, we used ChAT immunocytochemistry on alternate sections to those that were Nissl stained to identify motoneurons and complement the Nissl counts. Together, the ChAT+ and Nissl-stained somal counts showed that virtually all of the somata meeting the Nissl criteria for motoneurons were immunoreactive for ChAT at 21 d after the facial nerve sections. This combined approach serves to validate the Oppenheim criteria for identifying Nissl-stained motoneurons and indicates that a reduction of ChAT+ somata due to a loss or reduction in ChAT synthesis was not a significant contributor to our estimates of neuronal death by 2 1 d after the facial nerve sections. It suggests that the facial motoneurons that had lost sufficient ChAT synthesis to be immunocytochemically undetectable following axotomy (Hoover and Hancock, 1985) either had died or had recovered ChAT synthesis by 21 d after the axotomy.
The ability of deprenyl to induce increased survival of axotomized facial motoneurons is restricted to the (-)-enantiomer of the molecule over the dosage range tested in this study. This requirement for the (-)-stereoisomer appears to preclude the participation of MAO-B inhibition in the rescue mechanism. The data show that the threshold value for the R( -)-deprenylinduced rescue response must lie between 0.00 1 mg/kg/2d and 0.01 mg/kg/2d with an ED,, of about 0.005 mg/kg/2d. Two dosages of R(-)-deprenyl, that is, 0.01 mg/kg/2d and 10 mg/ kg/2d, were similarly potent in inducing increased motoneuronal survival. The 0.01 mg/kg dose of R(-)-deprenyl did not produce statistically significant inhibition of MAO-B while the 10.0 mg/kg dose caused at least 70% MAO-B inhibition. The 10 mg/kg/2d dose of S( +)-deprenyl did not induce an increase in motoneuronal survival but caused an average of 57% MAO-B inhibition. Hence, an R(-)-deprenyl dose insufficient to cause MAO-B inhibition did induce an apparently maximal increase in motoneuronal survival and a dose of S(+)-deprenyl that inhibited more than half of MAO-B activity did not increase motoneuronal survival.
It might be argued that the mliltipie doses of R(--)-deprenyl given every 2 d allowed significant MAO-B inhibition to accumulate over the 21 d of treatment (Waldmeier and Felner, 1978) and that the accumulated MAO-B inhibition induced the increased motoneuron survival. Several findings argue against that possibility. The facial motoneurons die quickly after axotomy at P14 such that 70% of the death has occurred by the third day after axotomy (W. Y. H. Ju, D. P. Holland, and W. G. Tatton, unpublished observations), and there is insufficient time for the doses to accumulate to a significant level of MAO-B inhibition. Furthermore, similar to the S( +)-deprenyl, doses producing 60% MAO-B inhibition while not increasing motoneuronal survival and doses of some other potent MAO inhibitors (e.g., iproniazid) that produce almost complete MAO-A and MAO-B inhibition do not increase the survival of the axotomized motoneuron (F. Zhang, D. P. Holland, K. S. Ansari, and W. G. Tatton, unpublished observations).
The results appear to demonstrate that P14 rat brainstem MAO-B activity is more sensitive to deprenyl than that in the adult brain. Increased sensitivity could be due to the different lipid microenvironment of MAO in the newborn brain. It is known that the kinetic parameters and sensitivity toward inhibitors of MAO are affected by the lipid components (Fowler and Oreland, 1980) . Stroline-Benedetti and Dostert (1989) reviewed age-related changes in brain MAO activities and showed that rat brainstem MAO-B activity remains constant after 7-8 weeks of age. The relatively increased levels of MAO-B inhibition obtained in the P14 rats might also be rationalized on the basis that glial cell differentiation is known to occur over the first 3 postnatal weeks in the rat (Hirano and Goldman, 1988; Folk-seang and Miller, 1992) and is likely incomplete at P14. MAO-B is concentrated in astroglia (Westlund et al., 1988) and the brainstem concentrations of the mRNA for glial acidic fibrillary protein, the intermediate filament in astrocytes, is about 30% of adult values at P14 (W. G. Tatton and N. A. Seniuk, unpublished observations) . Despite the increased sensitivity, the 20-fold difference in sensitivity of brainstem MAO-B inhibition to the (-)-and (+)-enantiomers is similar to that found in brain tissue from adult animals and appears in accord with the degree of stereosensitivity expected for the enzyme-substrate interaction (Stroline-Benedetti and Dostert, 1985) . The demonstration that the deprenyl-induced increase in the survival of immature motoneurons deprived of their musclederived trophic support shows pronounced stereospecificity and is not dependent on MAO-B inhibition could be compatible with an interaction involving R(-)-deprenyl that has characteristics more like those of classical receptor-ligand interactions than that of an enzyme-inhibitor interaction. Deprenyl binds to MAO-B irreversibly in a series of steps (Youdim, 1978) . The inhibition is initiated by the formation of a noncovalent complex with MAO-B in a reversible, competitive step. This transient intermediate complex leads to the oxidation of deprenyl and the reduction of the FAD prosthetic group. The next step is irreversible and consists of the covalent binding of oxidized deprenyl to the N-5 position of the isoalloxazine ring of the FAD moiety (Robinson, 1985; Cesura et al., 1987; Heinonen et al., 1989) . The modified flavin molecule reacts with a functional group on the enzyme surface through the reactive alkyl group, thus rendering the enzyme inactive toward normal substrate oxidation.
The doses of the two stereoisomers that we tested indicate at least a 2000-fold preference for the induction of rescue by R(-)-deprenyl. The mirror-image rotation of the (+)-enantiomer might be assumed to impede access to the site involved in motoneuronal rescue while it is considerably less impeded in its access to the FAD site of MAO-B. MAO-B is concentrated in glial cells in rodents (Vincent, 1989) and is located in the outer leaflets of mitochondria, but the cellular localization ofthe site involved in the motoneuronal rescue is unknown. It is not impossible that the rescue could depend on an interaction with a subtype of MAO-B that possesses extremely high sensitivity to R(-)-deprenyl and mediates substrate oxidation in a special environment or mediates some unknown function that contributes to neuronal survival. Alternately, the rescue may involve interaction with a molecule that is unrelated to MAO-B. The structure of MAO-B may offer some clues to the site involved in the rescue. Analysis of the base sequences of the genomic DNA encoding MAO-A and MAO-B suggests the presence of two FAD-binding domains; exon 12 encodes the FAD binding site and exons 1 and 2 may encode a recognition site that binds FAD noncovalently (Grimsby et al., 199 1) . The second site is reported to exhibit a high degree of homology with a number of other flavoproteins.
The finding that the rescue of the axotomized motoneurons appears independent of an interaction with MAO-B is in accord with work showing that R(-)-deprenyl was able to promote a marked increase in the survival of murine substantia nigra compacta neurons, after they had sustained lethal damage by MPTP, at dosages too low to cause any MAO inhibition (Tatton, 1993) . Similarly, the finding that the rescue of axotomized motoneurons occurs with doses too small to cause MAO-A inhibition is in accord with the finding that clorgyline, a selective MAO-A inhibitor, did not rescue MPTP-damaged substantia nigra neurons (Tatton, 1993) . We have found that pargyline, which inhibits both MAO-A and MAO-B and is structurally similar to deprenyl, increases the survival of the axotomized immature motoneuron but is considerably less effective on an equal molar basis . (-)-Methamphetamine and (-)-amphetamine, the major metabolites of R(-)-deprenyl, do not increase the survival of the motoneuron (K. S. Ansari, F. Zhang, and W. G. Tatton, unpublished observations). Further work with structural analogs of R(-)-deprenyl will be required to determine which portion(s) of the molecule determines the stereospecific interaction that induces motoneuronal rescue.
One other study (Finnegan et al., 1990) has shown that the protective action of deprenyl against DSP-4 (a noradrenergic toxin)-induced toxicity is not dependent upon MAO-B inhibition, as the duration of enzyme inhibition did not parallel the duration of the deprenyl-mediated protection. However, since R( -)-deprenyl has been shown to interfere with catecholamine uptake into neurons (Horsinget al., 1979; Hallman and Jonsson, 1984) , the possibility that the results reported in that study represent deprenyl-mediated blockade of neuronal DSP-4 uptake cannot be excluded. Control experiments involving delayed administration of deprenyl similar to those used to establish a second action for R( -)-deprenyl in MPTP parkinsonism (Tatton and Greenwood, 199 1) would be required to elucidate the action of deprenyl on DSP-4 toxicity.
The mechanism by which R( -)-deprenyl rescues the axotomized motoneuron is unknown. It would seem plausible, however, to suggest that deprenyl induces compensation for loss of targetderived trophic support. This does not imply that R(-)-deprenyl itself acts as a trophic factor but rather that it interferes with or triggers some event that supports the survival of motoneurons after the withdrawal of the trophic support. Recent research has shown that the neurotrophic factors bFGF (Grothe and Unsicker, 1992 ) BDNF (Sendtner et al., 1992; Yan et al., 1992) , and CNTF (Sendtner et al., 1990 ) reduce axotomy-induced death of facial or hypoglossal motoneurons in neonatal or immature rats in experiments similar to ours with R(-)-deprenyl.
CNTF reportedly increased the survival of facial motoneurons axotomized at Pl from approximately 24% to about 80% (Sendtner et al., 1990) and BDNF increased the survival to about 55% at the same age (Sendtner et al., 1992; Yan et al., 1992) . Direct comparison to our findings at P14 with R(-)-deprenyl may be complicated by the approximately 15-20% naturally occurring motoneuronal death that occurs between Pl and P8 in the rat (Rootman et al., 1981) . Hence, motoneuronal death due to a loss of target-derived trophic support may be superimposed on naturally occurring motoneuronal death when axotomy is carried out at Pl. bFGF increased the survival of hypoglossal motoneurons axotomized at P7 from about 12% to about 24% (Grothe and Unsicker, 1992) . In any case, by treating the animals with R( -)-deprenyl every second day, we achieved an increase in survival that is within the same range as that induced by the three neurotrophic factors.
Yet our schedule of treating the immature animals every 48 hr with the R(-)-deprenyl may not be optimal. We initially designed our experiments based on the premise that an action of R(-)-deprenyl would be dependent on MAO-B inhibition (Tatton and Greenwood, 199 1; Salo and Tatton, 1992) . The half-life of MAO-B inhibition by R(-)-deprenyl in rodents is 5-7 d (Heinonen and Lammintausta, 199 l) , so we reasoned that a dose every second day was adequate and would in fact cause the MAO-B inhibition to cumulate over the 21 d of treatment every second day (Tatton, 1993) . The present study indicates that brain concentrations of 1 O-6 M or less can induce increased survival of the axotomized motoneuron. The 1O-6 M concentration is based on the 0.01 mg/kg dosage and an assumption that MAO-B is equally distributed in the rat tissues. Since MAO-B is concentrated in hepatic cells and circulating cells like platelets to a greater extent than in brain tissues (Kalari et al., 1988; Riachi and Harik, 1992) , it is likely that brain concentrations are lower than those predicted on the basis of equal whole-body distribution. The half-life of R(-)-deprenyl in rodents is about 1.5 hr (Heinonen et al., 1989) ; hence, the treatment schedules we have used to date have offered pulses of R( -)-deprenyl only every 48 hr and yet have been effective at 0.01 mg/kg. Continuous infusion of R(-)-deprenyl might induce greater survival of the axotomized motoneuron.
Given the similar dosages required for neuronal rescue and the independence of the increased survival from MAO-B inhibition, it is likely that the mechanism involved in the rescue of axotomized immature motoneurons is the same as that mediating the rescue of MPTP-damaged dopaminergic neurons (Tatton and Greenwood, 1991; Tatton, 1993) . Similarly, an MAO-independent rescue mechanism could conceivably account for the reported slowing of the progression of PD and AD by R(-)-deprenyl (Tatton, 1993) . A rescue mechanism as opposed to neuroprotection would not require a common basis for damage to the largely different neuronal populations that degenerate in the two diseases.
In conclusion, if the deprenyl-induced rescue of axotomized facial motoneurons does involve a high-affinity, stereospecific interaction with an as yet unknown site, the characterization and identification of the site could provide new insights into the processes that influence neuronal survival.
